Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chimeric TherapeuticsCHMMF -96.67%13 3-Year EBITDA Growth Rate is 41.80% as of Dec. 2025, which is 2% above its 10-year median of 41.05. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Chimeric Therapeutics ranks better than 79.75% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 41.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Chimeric Therapeutics was 41.80% per year. The lowest was 40.30% per year. And the median was 41.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Chimeric Therapeutics 3-Year EBITDA Growth Rate Related Terms
CHMMF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Chimeric Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 41.80% mean?
Chimeric Therapeutics (CHMMF) has a 3-Year EBITDA Growth Rate of 41.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chimeric Therapeutics and its competitors. This is near median its historical median of 41.05. Over the past decade, Chimeric Therapeutics' 3-Year EBITDA Growth Rate has ranged from 40.30 to 41.80. According to the industry distribution chart, Chimeric Therapeutics ranks #229 out of 1131 companies in the Biotechnology industry, placing it in the top 20.2%.
Is Chimeric Therapeutics' 3-Year EBITDA Growth Rate too high?
Chimeric Therapeutics' current 3-Year EBITDA Growth Rate of 41.80% is near median its 10-year median of 41.05. Over the past 10 years, this metric has ranged from a low of 40.30 to a high of 41.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Chimeric Therapeutics' value of 41.80% is 180.5% above this industry median. Based on the distribution chart, Chimeric Therapeutics ranks #229 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #229 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Chimeric Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Chimeric Therapeutics' value of 41.80% is 180.5% above this benchmark. Historically, Chimeric Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 40.30 to 41.80 over the past decade. While the company's 10-year median is 41.05 vs. the industry median of 14.90, Chimeric Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chimeric Therapeutics's current 3-Year EBITDA Growth Rate of 41.80% is 180.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chimeric Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimeric Therapeutics's current 3-Year EBITDA Growth Rate is 41.80%, which is near median its own 10-year median of 41.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current 3-Year EBITDA Growth Rate of 41.80%. The current 3-Year EBITDA Growth Rate is 41.80%, which is near median its 10-year median of 41.05 and 180.5% above the Biotechnology industry median of 14.90. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current 3-Year EBITDA Growth Rate is 41.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
